Palvella Therapeutics (PVLA) CEO receives 124,603 stock option award

Rhea-AI Filing Summary

Palvella Therapeutics President and CEO Wes Kaupinen received a grant of 124,603 stock options on February 5, 2026. The options have an exercise price of $76.43 per share and are held directly.

The award vests in equal monthly installments over 48 months starting February 5, 2026, contingent on his continued service. Following this grant, Kaupinen beneficially owns 124,603 derivative securities tied to Palvella Therapeutics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaupinen Wes

(Last) (First) (Middle)

C/O PALVELLA THERAPEUTICS, INC.

353 W. LANCASTER AVENUE, SUITE 200

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [ PVLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$76.43	02/05/2026		A		124,603		(1)	02/05/2036	Common Stock	124,603	$0	124,603	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

	/s/ Kathleen A. McGowan, Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Palvella Therapeutics (PVLA) report in this Form 4 filing?

Palvella Therapeutics reported that President and CEO Wes Kaupinen received 124,603 stock options on February 5, 2026. These options relate to the company’s common stock and are classified as derivative securities held directly by him.

How many stock options did PVLA CEO Wes Kaupinen receive and at what price?

Wes Kaupinen received 124,603 stock options with an exercise price of $76.43 per share. These options give him the right to buy Palvella Therapeutics common stock at that price if and when they become fully vested and exercisable.

When do Wes Kaupinen’s Palvella Therapeutics stock options vest?

The stock options vest in equal monthly installments over 48 months, starting on February 5, 2026. Vesting is conditioned on Kaupinen’s continuous service with Palvella Therapeutics through each monthly vesting date specified in the grant terms.

What is Wes Kaupinen’s derivative securities ownership after this PVLA grant?

After this grant, Wes Kaupinen beneficially owns 124,603 derivative securities related to Palvella Therapeutics common stock. These consist of the newly granted stock options reported in the filing, all held in direct ownership according to the reported data.

Is the stock option grant to PVLA’s CEO a purchase or an award?

The Form 4 lists transaction code “A”, indicating an award or grant of stock options rather than an open-market purchase. The grant provides future rights to acquire shares at $76.43 per share, subject to the vesting schedule and service conditions.